Phuong-Thu Pham, MD
Nephrology · Los Angeles, CANPI 1699795856
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,650 of the $1,917 with a category attached, or 86.1%. Novartis accounts for 90.0% of it on its own, with 2 other manufacturers making up the rest.
Across 4 payments — averaging $479.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- AstraZeneca$120
- Sanofi-aventis U.S. LLC$72
Across 4 payments — averaging $32,361 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$129K
What the payments were for
- Consulting fees$1,65086%
- Food & beverage$19510%
- Education$724%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 2 | $1,725 |
| AstraZeneca | 1 | $120 |
| Sanofi-aventis U.S. LLC | 1 | $72 |
How this compares
$1,917 in reported general payments places this provider in the 60th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cinacalcet Hcl | 46 | $21,738 |
| Atovaquone | 16 | $13,718 |
| Mycophenolate Mofetil | 16 | $3,560 |
| Valganciclovir Hcl | 18 | $2,236 |
| Tacrolimus | 13 | $1,483 |
| Fluconazole | 28 | $1,149 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 17 | $1,013 |
| Prednisone | 97 | $651 |
| Nifedipine ErNifedipine | 17 | $549 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 64 | $516 |
| Pantoprazole Sodium | 51 | $445 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 15 | $384 |
| Atorvastatin Calcium | 30 | $320 |
| Tamsulosin Hcl | 24 | $235 |
| Carvedilol | 52 | $234 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Los Angeles
- Anjay RastogiLos Angeles$2.2M
- Suphamai BunnapradistLos Angeles$498K
- Mohammad KamgarLos Angeles$497K
- Victor CarabelloLos Angeles$363K
- Tariq ShahLos Angeles$351K
- Susanne NicholasLos Angeles$146K
- Arishia GhaffariLos Angeles$142K
- Allen NissensonLos Angeles$101K
- Niloofar NobakhtLos Angeles$97K
- Farid ArmanLos Angeles$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.